Jefferies Group reissues “buy” rating for AmSurg stock: 5 points

Jefferies Group reiterated AmSurg stock’s “buy” rating, according to a Newsway 21 report.

Advertisement

Here are five points:

1. Jefferies Group currently has a $96 target price on the stock.

2. AmSurg has a consensus rating of “buy” and an average target price of $93.20 from all the brokerages covering the stock.

3. The firm’s 50-day moving average is $76.73 and its 200-day moving average is $75.07.

4. AmSurg has a one-year low of $54.11 and a one-year high of $87.42.

5. The company has a market capitalization of $4.12 billion.

More articles on ASC issues:
ASC administrator tip of the day: Maria Freed from Coral Gables Surgery Center
6 insights into MIS GI surgery — NOTES, POEM & more
One ASC’s experience bundling payments for colonoscopy reaps success: 6 takeaways

Advertisement

Next Up in ASC Transactions & Valuation Issues

  • Leawood, Kan.-based ASC company NueHealth announced four ASC partnerships across Missouri and New Jersey, according to a Jan. 21 news…

  • Here are five recent updates on retail giant Walgreens and its busy year in healthcare mergers, acquisitions and regulatory conflict:…

Advertisement

Comments are closed.